Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b

S. Markovic-Plese, B. Bielekova, N. Kadom, T. P. Leist, R. Martin, J. A. Frank, H. F. McFarland

Research output: Contribution to journalArticlepeer-review

Abstract

An open-label study was performed to assess the effectiveness of oral azathioprine (AZA) on augmenting the response to interferon β-1b (IFNβ-1b) in patients with treatment-refractory relapsing-remitting MS. Six IFNβ-1b-treated MS patients with continued disease activity were studied on IFNβ-1b and AZA therapy for a median period of 15 months. A 69% reduction in the number of contrast-enhancing lesions was observed during the combination therapy (p = 0.002).

Original languageEnglish (US)
Pages (from-to)1849-1851
Number of pages3
JournalNeurology
Volume60
Issue number11
StatePublished - Jun 10 2003
Externally publishedYes

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Longitudinal MRI study: The effects of azathioprine in MS patients refractory to interferon β-1b'. Together they form a unique fingerprint.

Cite this